Overview
Since the first solid organ transplant in 1954, clinicians have continued to struggle with maintaining balance between immunosuppression and alloimmune responses. Transplant recipients are typically saddled with a lifetime of deleterious but necessary immunosuppressive agents that ultimately lead to additional forms of end organ damage, infections, and cancer. The goal of our laboratory is to uncover methods to decrease the immunosuppressive burden our patients experience and understand how we can achieve allograft tolerance.